As previously reported, Guggenheim analyst Seamus Fernandez downgraded Sanofi (SNY) to Neutral from Buy and removed the firm’s previous price target on the shares. The firm had hoped to see materially improved pipeline-driven upside, but this “failed to materialize” and it now sees no thesis changing pipeline catalysts for at least the next 12 months, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi downgraded to Neutral from Buy at Guggenheim
- Sanofi downgraded to Neutral from Overweight at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower